Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ingAccesswire • 02/14/23
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023Accesswire • 02/07/23
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26thGlobeNewsWire • 01/10/23
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in AustraliaAccesswire • 12/02/22
Altamira Therapeutics Provides Business Update and First Half 2022 Financial ResultsGlobeNewsWire • 11/30/22
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance PharmaGlobeNewsWire • 11/30/22
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque StabilityAccesswire • 11/22/22
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid EventGlobeNewsWire • 11/10/22
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid RequirementGlobeNewsWire • 11/09/22
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira's Bentrio under Controlled Grass Pollen ExposureGlobeNewsWire • 11/08/22
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in AustraliaGlobeNewsWire • 10/03/22
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19GlobeNewsWire • 09/13/22
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development SummitGlobeNewsWire • 09/08/22
Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic TransformationGlobeNewsWire • 08/03/22
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19GlobeNewsWire • 08/01/22